0001062822-20-000073.txt : 20201117 0001062822-20-000073.hdr.sgml : 20201117 20201117072220 ACCESSION NUMBER: 0001062822-20-000073 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20201116 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201117 DATE AS OF CHANGE: 20201117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LEXICON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001062822 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 760474169 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30111 FILM NUMBER: 201319259 BUSINESS ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 BUSINESS PHONE: 2818633000 MAIL ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON PHARMACEUTICALS, INC./DE DATE OF NAME CHANGE: 20070426 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON GENETICS INC/TX DATE OF NAME CHANGE: 20000126 8-K 1 lxrx-20201116.htm 8-K lxrx-20201116
0001062822FALSE00010628222020-11-162020-11-16



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________

FORM 8-K
__________________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2020

Lexicon Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware000-3011176-0474169
(State or other jurisdiction of
incorporation or organization)		(Commission File Number)(I.R.S. Employer
Identification Number)

8800 Technology Forest Place
The Woodlands, Texas 77381
(Address of principal executive offices and Zip Code)

(281) 863-3000
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001LXRXThe Nasdaq Global Select Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 8.01     Other Events

On November 16, 2020, we issued a press release announcing results from our SCORED and SOLOIST Phase 3 clinical trials of sotagliflozin, the presentation of such results at the American Heart Association Scientific Sessions 2020 and the publication of such results in The New England Journal of Medicine. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and incorporated herein by this reference.



Item 9.01    Financial Statements and Exhibits

(d)    Exhibits





Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Lexicon Pharmaceuticals, Inc.
Date: November 17, 2020By:/s/ Brian T. Crum
Brian T. Crum
Vice President and General Counsel



Index to Exhibits




 EX-99.1 2 pressreleaseahasotagli.htm EX-99.1 Document

                                            Exhibit 99.1

RESULTS FROM SOLOIST AND SCORED OUTCOMES STUDIES
PRESENTED AT LATE-BREAKING SCIENCE SESSION OF
AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS AND
PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies

The Woodlands, Texas, November 16, 2020 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.

In the SOLOIST study, the primary endpoint was achieved with a hazard ratio (HR) of 0.67 (p<0.001) in people with type 2 diabetes and a recent hospitalization for worsening heart failure. In the SCORED study, the primary endpoint was achieved with a hazard ratio of 0.74 (p<0.001) in people with type 2 diabetes and chronic kidney disease with an estimated glomerular filtration rate (eGFR) of 25 to 60 ml/minute per 1.73 m2 of body-surface area.

The key results from SOLOIST and SCORED were presented today at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” and “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.” The articles may be accessed at www.nejm.org.

“Cardiovascular disease continues to be a leading cause of death in people with type 2 diabetes,” said Deepak L. Bhatt, M.D., M.P.H., executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital and a professor of medicine at Harvard Medical School and study chair and lead author for the NEJM publications of the SOLOIST and SCORED results. “SOLOIST demonstrates that early, in-hospital initiation of sotagliflozin in patients with worsening heart failure significantly reduces subsequent cardiovascular events, an effect that was consistent across groups with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). SCORED demonstrates that sotagliflozin significantly reduces heart failure events in a patient population with stage 3 and 4 chronic kidney disease and cardiovascular risk. Both studies add to the evidence that SGLT2 inhibition should be standard of care in heart failure, and the SCORED data reflecting a reduction in myocardial infarction and stroke and better glucose control in CKD patients suggest potential benefits from the dual SGLT1 and SGLT2 mechanism of this particular agent.”

Key SOLOIST Phase 3 Study Results

SOLOIST was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 1,222 patients with type 2 diabetes who had recently been hospitalized for worsening heart failure. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients starting treatment with 200 mg sotagliflozin


once daily compared with placebo, with dosing initiated either before or within 3 days of hospital discharge.

The first dose of sotagliflozin or placebo was administered prior to hospital discharge in 48.8% of the patients and a median of two days after discharge in 51.2% of the patients, with the benefits of sotagliflozin being consistent between those prespecified subgroups of patients. The initial 200 mg once daily dose of sotagliflozin was increased to 400 mg once daily if unacceptable side effects did not occur.

Treatment with sotagliflozin resulted in a significantly lower total number of cardiovascular deaths, heart failure hospitalizations and urgent visits as compared to placebo. A total of 600 primary endpoint events occurred in the study, with 245 events in the sotagliflozin treated group and 355 events in the placebo group. There were 51.0 primary endpoint events per 100 patient-years in the sotagliflozin treated group as compared to 76.3 events per 100 patient-years in the placebo group (HR=0.67; 95% confidence interval [CI]=0.52 to 0.85; p<0.001). There were 10.6 events of cardiovascular death per 100 patient-years in the sotagliflozin treated group as compared to 12.5 events per 100 patient-years in the placebo group (HR=0.84; 95% CI=0.58 to 1.22; p=0.36).

Of note, effects on the primary endpoint were consistent among patients suffering from heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), with a hazard ratio of 0.72 (95% CI=0.56 to 0.94) in patients with a left ventricular ejection fraction (LVEF) of less than 50% and a hazard ratio of 0.48 (95% CI=0.27 to 0.86) in patients with a LVEF of greater than or equal to 50%.

Serious adverse events that led to discontinuation of study drug, as determined by investigators, occurred in 3.0% (n=18) of the patients in the sotagliflozin treated group and in 2.8% (n=17) of the patients in the placebo group. Based on investigator reported events, the most common adverse events of special interest included hypotension (6.0% on sotagliflozin versus 4.6% on placebo), urinary tract infections (4.8% on sotagliflozin versus 5.1% on placebo), acute kidney injury (4.1% on sotagliflozin versus 4.4% on placebo), and diarrhea (6.1% on sotagliflozin versus 3.4% on placebo). Among other adverse events of interest, in SOLOIST, genital mycotic infections (0.8% on sotagliflozin vs. 0.2% on placebo) were infrequent, severe hypoglycemia (1.5% on sotagliflozin vs. 0.3% on placebo) was more common in the sotagliflozin treated group and diabetic ketoacidosis (0.3% on sotagliflozin vs. 0.7% on placebo) was similar between treatment groups.

The SOLOIST study was originally designed with a primary endpoint of the first occurrence of death from cardiovascular causes or hospitalization for heart failure, as determined by independent adjudication, but was modified in connection with the early close out of the study to include urgent heart failure visits and reflect the total number of events, as determined by investigators, in order to enhance the statistical power of the comparison. The specification of the primary endpoint based on total events was implemented without any awareness of the study outcomes or study-group assignments and without information from an interim analysis.

The results for first occurrence of cardiovascular death or hospitalization for heart failure (HR=0.71; 95% CI=0.57 to 0.89; p=0.003) based on investigator reported events were consistent with those of the modified primary endpoint.

Key SCORED Phase 3 Study Results

SCORED was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 10,584


patients with type 2 diabetes, chronic kidney disease with eGFR of 25 to 60 ml per minute per 1.73 m2 of body-surface area, and risks for cardiovascular disease. The primary endpoint was the total number of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo. The initial 200 mg once daily dose of sotagliflozin was increased to 400 mg once daily if unacceptable side effects did not occur.

Treatment with sotagliflozin resulted in a significantly lower total number of cardiovascular deaths, heart failure hospitalizations and urgent visits as compared to placebo. A total of 930 primary endpoint events occurred in the study, with 400 events in the sotagliflozin treated group and 530 events in the placebo group. There were 5.6 primary endpoint events per 100 patient-years in the sotagliflozin treated group as compared to 7.5 events per 100 patient-years in the placebo group (HR=0.74; 95% CI=0.63 to 0.88; p<0.001). There were 2.2 events of cardiovascular death per 100 patient-years in the sotagliflozin treated group as compared to 2.4 events per 100 patient-years in the placebo group (HR=0.90; 95% CI=0.73 to 1.12; p=0.35).

Of note, over the course of the study, the data showed an average reduction in hemoglobin A1c of 0.56% in the sotagliflozin treated group as compared to a reduction of 0.25% in the placebo group in patients with severe chronic kidney disease, eGFR less than 30 ml per minute per 1.73 m2 of body-surface area (p<0.001). In patients with moderate chronic kidney disease, eGFR greater than or equal to 30 ml per minute per 1.73 m2 of body-surface area, the data showed an average reduction in hemoglobin A1c of 0.60% in the sotagliflozin treated group as compared to a reduction of 0.17% in the placebo group (p<0.001).

Serious adverse events that led to discontinuation of study drug, as determined by investigators, occurred in 2.1% (n=112) of the patients in the sotagliflozin treated group and in 1.8% (n=94) of the patients in the placebo group. Based on investigator reported events, the most common adverse events of special interest included urinary tract infections (11.5% on sotagliflozin versus 11.1% on placebo), diarrhea (8.5% on sotagliflozin versus 6.0% on placebo), volume depletion (5.3% on sotagliflozin versus 4.0% on placebo), bone fractures (2.1% on sotagliflozin versus 2.2% on placebo), and genital mycotic infections (2.4% on sotagliflozin versus 0.9% on placebo). Among other adverse events of interest, diabetic ketoacidosis (0.6% on sotagliflozin vs. 0.3% on placebo) was more common in the sotagliflozin treated group and severe hypoglycemia (1.0% on sotagliflozin vs. 1.0% on placebo) was similar between treatment groups.

The SCORED study was originally designed with co-primary endpoints, assessed in time-to-event analyses, of the first occurrence of a major adverse cardiovascular event (defined as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, or 3-point MACE) and the first occurrence of death from cardiovascular causes or hospitalization for heart failure, as determined by independent adjudication, but were modified in connection with the early close out of the study to include urgent heart failure visits and reflect the total number of events, as determined by investigators, in order to enhance the statistical power of the comparison. The specification of the primary endpoint based on total events was implemented without any awareness of the study outcomes or study-group assignments and without information from an interim analysis.

In a time-to-event analysis, applying the original co-primary endpoints based on investigator reported events, the results for both the first occurrence of a MACE event (HR=0.84; 95% CI=0.72 to 0.99; p=0.035) and the first occurrence of death from cardiovascular causes or hospitalization for heart failure (HR=0.78; 95% CI=0.66 to 0.91; p=0.001) were consistent with those of the modified primary endpoint.



About Sotagliflozin

Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin is approved in the European Union (EU) for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes with a body mass index ≥ 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy, but has not yet been commercially launched.

About Lexicon Pharmaceuticals

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in diabetes and metabolism, neuropathic pain and other indications. For additional information, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements,” including statements relating to Lexicon’s clinical development of sotagliflozin and the clinical development and therapeutic and commercial potential of sotagliflozin. In addition, this press release also contains forward looking statements relating to Lexicon’s financial position, long term outlook on its business, growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the risk that the FDA and other regulatory authorities may not grant regulatory approval of sotagliflozin, and the risk that such regulatory approvals, if granted, may have significant limitations on the approved use of sotagliflozin. As a result, sotagliflozin may never be successfully commercialized. Other risks include Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211 and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.




For Inquiries:

Chas Schultz
Executive Director, Corporate Communications and Investor Relations
Lexicon Pharmaceuticals
(281) 863-3421
cschultz@lexpharma.com


 EX-101.SCH 3 lxrx-20201116.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 lxrx-20201116_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 lxrx-20201116_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 lxrx-20201116_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name City Area Code City Area Code Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 lxrx-20201116_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 lxrx-20201116_htm.xml IDEA: XBRL DOCUMENT 0001062822 2020-11-16 2020-11-16 0001062822 false 8-K 2020-11-16 Lexicon Pharmaceuticals, Inc. DE 000-30111 76-0474169 8800 Technology Forest Place The Woodlands TX 77381 281 863-3000 Common Stock, par value $0.001 LXRX NASDAQ false false false false false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Nov. 16, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 16, 2020
Entity Registrant Name Lexicon Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 000-30111
Entity Tax Identification Number 76-0474169
Entity Address, Address Line One 8800 Technology Forest Place
Entity Address, City or Town The Woodlands
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77381
City Area Code 281
Local Phone Number 863-3000
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol LXRX
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001062822
Amendment Flag false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.lexpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports lxrx-20201116.htm lxrx-20201116.xsd lxrx-20201116_cal.xml lxrx-20201116_def.xml lxrx-20201116_lab.xml lxrx-20201116_pre.xml pressreleaseahasotagli.htm http://xbrl.sec.gov/dei/2019-01-31 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lxrx-20201116.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "lxrx-20201116_cal.xml" ] }, "definitionLink": { "local": [ "lxrx-20201116_def.xml" ] }, "inline": { "local": [ "lxrx-20201116.htm" ] }, "labelLink": { "local": [ "lxrx-20201116_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "lxrx-20201116_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "lxrx-20201116.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lxrx", "nsuri": "http://www.lexpharma.com/20201116", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20201116.htm", "contextRef": "i270954990545440a902712dda84cdeec_D20201116-20201116", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.lexpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20201116.htm", "contextRef": "i270954990545440a902712dda84cdeec_D20201116-20201116", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001062822-20-000073-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001062822-20-000073-xbrl.zip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